Verition Fund Management LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB)

Verition Fund Management LLC purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 22,036 shares of the biotechnology company’s stock, valued at approximately $738,000.

A number of other large investors also recently made changes to their positions in ANAB. Values First Advisors Inc. acquired a new position in AnaptysBio in the third quarter valued at $49,000. nVerses Capital LLC grew its holdings in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the period. Headlands Technologies LLC increased its stake in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 2,600 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of AnaptysBio during the 3rd quarter worth about $229,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ANAB shares. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Wedbush reiterated an “outperform” rating and issued a $42.00 target price on shares of AnaptysBio in a report on Thursday, November 14th. Truist Financial upped their price target on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Finally, Guggenheim lifted their price objective on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus price target of $54.64.

Insider Buying and Selling

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at $189,333.04. This represents a 72.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock valued at $892,936 in the last quarter. Company insiders own 33.70% of the company’s stock.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB opened at $22.88 on Tuesday. The business’s 50-day simple moving average is $26.95 and its 200 day simple moving average is $29.69. The company has a market cap of $696.24 million, a P/E ratio of -3.76 and a beta of -0.11. AnaptysBio, Inc. has a one year low of $15.84 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. Analysts predict that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.